GL1X · GenesisL1 explorer

MolNFT v1 · #125402 · protein

Afamin antibody fragment, N14 Fab, L1- glycosylated, crystal form II

5L7X · Mouse antibody Fab fragment, IGG1-kappa heavy chain: “Afamin antibody fragment, N14 Fab, L1- glycosylated, crystal form II”. X-ray diffraction, 1 ligand (NAG), 4 pockets (best druggability 0.57). MolNFT v1 #125402 on GenesisL1: 3D…

PDB
5L7X
Type
protein
Length
419 residues
Chains
2
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Mouse antibody Fab fragment, IGG1-kappa heavy chain; Mouse antibody Fab fragment…
Ligands
NAG
Pockets
4 · best druggability 0.57

Structure

x-ray diffraction · 2 distinct chains · 8% helix, 53% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
HMouse antibody Fab fragment, IGG1-kappa heavy chainprotein2059% helix, 55% strand—
LMouse antibody Fab fragment, IGG1-kappa light chainprotein2147% helix, 51% strand—

Ligands and binding sites

  • NAG · 2-acetamido-2-deoxy-beta-D-glucopyranose · sugar · chains L
  • PEG · Di(hydroxyethyl)ether · additive · 3 copies · chains H, L
  • PG4 · Tetraethylene glycol · additive · chains H
  • 1PE · Pentaethylene glycol · additive · chains H, L

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

4 pockets found on a 1 Å grid, 1 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
13610.570.7647PEG
2520.330.7816empty
3680.310.75201PE
4520.260.7316empty

Interfaces

1 interface between chains.

  • H–L · 1808 Ų buried · 18 hydrogen bonds · protein-protein

Modifications

Observed in the structure: 4 disulfide, 1 glycan (disulfide, N-glycosylation).

Compared structures

  • 5L7X · Afamin antibody fragment, N14 Fab, L1- glycosylated, crystal form II · the same entry in another collection · chain H against H, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.